Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14500237 | 0.85 | MET (0.36) | GABRA1LMNAGABRG2GABRB3CYP1A2 | |
| SCHEMBL10263016 | 0.85 | MET (0.36) | GABRA1LMNAGABRG2GABRB3CYP1A2 | |
| SCHEMBL18905193 | 0.82 | CYP1A2 (0.47) | GABRA1LMNAGABRG2GABRB3CYP1A2 | |
| SCHEMBL14493403 | 0.82 | CYP1A2 (0.37) | LMNACYP1A2CYP3A4HPGDTSHR | |
| SCHEMBL2609313 | 0.81 | MASP2 (0.36) | CYP1A2KDM4EGPR3MAPTEGFR | |
| SCHEMBL18368376 | 0.81 | ALOX5AP (0.36) | GABRA1LMNAGABRG2GABRB3CYP1A2 | |
| SCHEMBL26854288 | 0.81 | PDGFRB (0.48) | KDM4EGPR3LRRK2ALOX5APFEN1 | |
| SCHEMBL14493346 | 0.81 | ALDH1A1 (0.46) | LMNACYP1A2CYP3A4HPGDTSHR | |
| SCHEMBL2285438 | 0.79 | GPR3 (0.46) | LMNACYP1A2KDM4EGPR3LRRK2 | |
| SCHEMBL21783731 | 0.78 | MTNR1B (0.47) | GABRA1GABRG2GABRB3CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135723-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230135723-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230026466-A1 | WDR5 INHIBITORS AND MODULATORS | VANDERBILT UNIVERSITY | 2023-01-26 | — | — | US | disclosed |
| US-20200239553-A1 | BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same | ABBVIE INC. (US) | 2020-07-30 | — | — | US | disclosed |
| US-10640563-B2 | Anti-B7-H3 antibodies and antibody drug conjugates | ABBVIE INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20200121803-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2020-04-23 | — | — | US | disclosed |
| US-20190343961-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2019-11-14 | — | — | US | disclosed |
| US-20190153108-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2019-05-23 | — | — | US | disclosed |
| US-20190142941-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2019-05-16 | — | — | US | disclosed |
| US-20170355769-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355769-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2017-12-14 | — | — | US | disclosed |
| US-20160339117-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC. (US) | 2016-11-24 | — | — | US | disclosed |
| US-20160158377-A1 | BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same | ABBVIE INC. (US) | 2016-06-09 | — | — | US | disclosed |
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239553-A1 | BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same | BCL2, BCL2L10, BAX | GABRA1 1442/4885LMNA 3443/4885GABRG2 561/4885 |
| US-20230135723-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | CD99, SLC3A2, CD63 | GABRA1 603/4885LMNA 2930/4885GABRG2 416/4885 |
| US-20230026466-A1 | WDR5 INHIBITORS AND MODULATORS | WDR5, WDR1, WDR3 | GABRA1 3838/4885LMNA 3551/4885GABRG2 3527/4885 |
| US-20170355769-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | HRH3, H1-3, CD274 | GABRA1 1458/4885LMNA 4613/4885GABRG2 1526/4885 |
| US-10640563-B2 | Anti-B7-H3 antibodies and antibody drug conjugates | HRH3, H1-3, CD274 | GABRA1 1458/4885LMNA 4613/4885GABRG2 1526/4885 |
| US-20160339117-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | GABRA1 1492/4885LMNA 1814/4885GABRG2 485/4885 |
| US-20190343961-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | GABRA1 660/4885LMNA 4516/4885GABRG2 219/4885 |
| US-20160158377-A1 | BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same | BCL2, BCL2L10, BAX | GABRA1 1442/4885LMNA 3443/4885GABRG2 561/4885 |
| US-20190142941-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | GABRA1 1492/4885LMNA 1814/4885GABRG2 485/4885 |
| US-20190153108-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | GABRA1 660/4885LMNA 4516/4885GABRG2 219/4885 |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MAP3K20, MAP3K1, MAP3K5 | GABRA1 2619/4885LMNA 2237/4885GABRG2 2616/4885 |
| US-20200121803-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | CD99, SLC3A2, CD63 | GABRA1 603/4885LMNA 2930/4885GABRG2 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.